{"id":61812,"date":"2026-03-30T15:13:35","date_gmt":"2026-03-30T07:13:35","guid":{"rendered":"https:\/\/flcube.com\/?p=61812"},"modified":"2026-03-30T15:13:36","modified_gmt":"2026-03-30T07:13:36","slug":"eli-lillys-taltz-zepbound-combo-shows-superior-efficacy-in-obese-psoriatic-arthritis-patients-in-phase-iiib-together-psa-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61812","title":{"rendered":"Eli Lilly\u2019s Taltz-Zepbound Combo Shows Superior Efficacy in Obese Psoriatic Arthritis Patients in Phase IIIb TOGETHER-PsA Trial"},"content":{"rendered":"\n<p><strong>Eli Lilly and Company<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) reported positive top-line results from the <strong>TOGETHER-PsA Phase IIIb open-label trial<\/strong>, demonstrating that the combination of <strong>Taltz\u00ae (ixekizumab)<\/strong> and <strong>Zepbound\u2122 (tirzepatide)<\/strong> achieved <strong>statistically superior efficacy<\/strong> versus <strong>Taltz monotherapy<\/strong> in adults with <strong>active psoriatic arthritis (PsA)<\/strong> who are <strong>overweight or obese<\/strong> and have at least one weight-related comorbidity. At the <strong>36-week primary endpoint<\/strong>, the dual-therapy regimen met <strong>all primary and key secondary endpoints<\/strong>, reinforcing Lilly\u2019s strategy of integrating its immunology and metabolic franchises.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-design-amp-outcomes\">Clinical Trial Design &amp; Outcomes<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Taltz + Zepbound<\/th><th>Taltz Monotherapy<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td><strong>Population<\/strong><\/td><td>Adults with active PsA, BMI \u226527 + \u22651 weight-related comorbidity<\/td><td>Same<\/td><td>High-unmet-need subgroup<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>ACR50 response at Week 36<\/td><td>\u2014<\/td><td><strong>Met with statistical superiority<\/strong><\/td><\/tr><tr><td><strong>Key Secondary Endpoints<\/strong><\/td><td>ACR20\/70, HAQ-DI, enthesitis resolution, dactylitis clearance<\/td><td>\u2014<\/td><td><strong>All met<\/strong><\/td><\/tr><tr><td><strong>Mechanistic Rationale<\/strong><\/td><td>Dual targeting: IL-17A inflammation + GLP-1\/GIP-mediated metabolic improvement<\/td><td>IL-17A inhibition only<\/td><td>Addresses obesity-driven inflammation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The data suggest that <strong>weight loss and metabolic modulation via tirzepatide may potentiate the anti-inflammatory effects of ixekizumab<\/strong> in this metabolically complex PsA cohort.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profiles\">Drug Profiles<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-taltz-ixekizumab\"><strong>Taltz\u00ae (ixekizumab)<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class<\/strong>: Humanized monoclonal antibody<\/li>\n\n\n\n<li><strong>Target<\/strong>: Interleukin-17A (IL-17A)<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Binds IL-17A with high affinity, blocking interaction with IL-17 receptor \u2192 suppresses release of pro-inflammatory cytokines (e.g., IL-6, TNF-\u03b1) and chemokines<\/li>\n\n\n\n<li><strong>Approved Indications<\/strong>: Psoriasis, PsA, axial spondyloarthritis<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-zepbound-tirzepatide\"><strong>Zepbound\u2122 (tirzepatide)<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class<\/strong>: Dual GIP\/GLP-1 receptor agonist<\/li>\n\n\n\n<li><strong>Primary Use<\/strong>: Obesity and type 2 diabetes<\/li>\n\n\n\n<li><strong>Relevance in PsA<\/strong>: Reduces adipose tissue inflammation, improves insulin sensitivity, and lowers systemic cytokine burden<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Franchise Synergy<\/strong>: First clinical validation of combining Lilly\u2019s <strong>immunology (Taltz)<\/strong> and <strong>obesity (Zepbound)<\/strong> blockbusters<\/li>\n\n\n\n<li><strong>Market Differentiation<\/strong>: Targets ~60% of PsA patients who are overweight\/obese\u2014a segment with <strong>reduced response to conventional biologics<\/strong><\/li>\n\n\n\n<li><strong>Commercial Upside<\/strong>: Potential for <strong>combination labeling<\/strong> and premium pricing in a $6B+ global PsA market<\/li>\n\n\n\n<li><strong>Pipeline Signal<\/strong>: May inform future trials in other immune-metabolic conditions (e.g., hidradenitis suppurativa, NASH-associated arthritis)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-context\">Competitive Context<\/h2>\n\n\n\n<p>While rivals focus on single-pathway inhibition (e.g., JAK, IL-23, TNF), Lilly\u2019s approach leverages <strong>multi-system biology<\/strong>\u2014addressing both <strong>joint inflammation<\/strong> and its <strong>metabolic drivers<\/strong>. This could position the combo as a preferred regimen for <strong>comorbid PsA patients<\/strong>, a growing demographic worldwide.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential. Actual outcomes may differ due to FDA\/EMA review, safety findings, and market adoption dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company (NYSE: LLY) reported positive top-line results from the TOGETHER-PsA Phase IIIb&#8230;<\/p>\n","protected":false},"author":1,"featured_media":61817,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,17,199,911],"class_list":["post-61812","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-auto-immune","tag-clinical-trial-results","tag-eli-lilly","tag-nyse-lly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly\u2019s Taltz-Zepbound Combo Shows Superior Efficacy in Obese Psoriatic Arthritis Patients in Phase IIIb TOGETHER-PsA Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE: LLY) reported positive top-line results from the TOGETHER-PsA Phase IIIb open-label trial, demonstrating that the combination of Taltz\u00ae (ixekizumab) and Zepbound\u2122 (tirzepatide) achieved statistically superior efficacy versus Taltz monotherapy in adults with active psoriatic arthritis (PsA) who are overweight or obese and have at least one weight-related comorbidity. At the 36-week primary endpoint, the dual-therapy regimen met all primary and key secondary endpoints, reinforcing Lilly\u2019s strategy of integrating its immunology and metabolic franchises.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=61812\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly\u2019s Taltz-Zepbound Combo Shows Superior Efficacy in Obese Psoriatic Arthritis Patients in Phase IIIb TOGETHER-PsA Trial\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company (NYSE: LLY) reported positive top-line results from the TOGETHER-PsA Phase IIIb open-label trial, demonstrating that the combination of Taltz\u00ae (ixekizumab) and Zepbound\u2122 (tirzepatide) achieved statistically superior efficacy versus Taltz monotherapy in adults with active psoriatic arthritis (PsA) who are overweight or obese and have at least one weight-related comorbidity. At the 36-week primary endpoint, the dual-therapy regimen met all primary and key secondary endpoints, reinforcing Lilly\u2019s strategy of integrating its immunology and metabolic franchises.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=61812\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-30T07:13:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-30T07:13:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3004.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61812#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61812\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly\u2019s Taltz-Zepbound Combo Shows Superior Efficacy in Obese Psoriatic Arthritis Patients in Phase IIIb TOGETHER-PsA Trial\",\"datePublished\":\"2026-03-30T07:13:35+00:00\",\"dateModified\":\"2026-03-30T07:13:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61812\"},\"wordCount\":398,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61812#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3004.webp\",\"keywords\":[\"Auto-immune\",\"Clinical trial results\",\"Eli Lilly\",\"NYSE: LLY\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61812#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61812\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=61812\",\"name\":\"Eli Lilly\u2019s Taltz-Zepbound Combo Shows Superior Efficacy in Obese Psoriatic Arthritis Patients in Phase IIIb TOGETHER-PsA Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61812#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61812#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3004.webp\",\"datePublished\":\"2026-03-30T07:13:35+00:00\",\"dateModified\":\"2026-03-30T07:13:36+00:00\",\"description\":\"Eli Lilly and Company (NYSE: LLY) reported positive top-line results from the TOGETHER-PsA Phase IIIb open-label trial, demonstrating that the combination of Taltz\u00ae (ixekizumab) and Zepbound\u2122 (tirzepatide) achieved statistically superior efficacy versus Taltz monotherapy in adults with active psoriatic arthritis (PsA) who are overweight or obese and have at least one weight-related comorbidity. At the 36-week primary endpoint, the dual-therapy regimen met all primary and key secondary endpoints, reinforcing Lilly\u2019s strategy of integrating its immunology and metabolic franchises.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61812#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61812\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61812#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3004.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3004.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli Lilly\u2019s Taltz-Zepbound Combo Shows Superior Efficacy in Obese Psoriatic Arthritis Patients in Phase IIIb TOGETHER-PsA Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61812#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly\u2019s Taltz-Zepbound Combo Shows Superior Efficacy in Obese Psoriatic Arthritis Patients in Phase IIIb TOGETHER-PsA Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly\u2019s Taltz-Zepbound Combo Shows Superior Efficacy in Obese Psoriatic Arthritis Patients in Phase IIIb TOGETHER-PsA Trial - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE: LLY) reported positive top-line results from the TOGETHER-PsA Phase IIIb open-label trial, demonstrating that the combination of Taltz\u00ae (ixekizumab) and Zepbound\u2122 (tirzepatide) achieved statistically superior efficacy versus Taltz monotherapy in adults with active psoriatic arthritis (PsA) who are overweight or obese and have at least one weight-related comorbidity. At the 36-week primary endpoint, the dual-therapy regimen met all primary and key secondary endpoints, reinforcing Lilly\u2019s strategy of integrating its immunology and metabolic franchises.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=61812","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly\u2019s Taltz-Zepbound Combo Shows Superior Efficacy in Obese Psoriatic Arthritis Patients in Phase IIIb TOGETHER-PsA Trial","og_description":"Eli Lilly and Company (NYSE: LLY) reported positive top-line results from the TOGETHER-PsA Phase IIIb open-label trial, demonstrating that the combination of Taltz\u00ae (ixekizumab) and Zepbound\u2122 (tirzepatide) achieved statistically superior efficacy versus Taltz monotherapy in adults with active psoriatic arthritis (PsA) who are overweight or obese and have at least one weight-related comorbidity. At the 36-week primary endpoint, the dual-therapy regimen met all primary and key secondary endpoints, reinforcing Lilly\u2019s strategy of integrating its immunology and metabolic franchises.","og_url":"https:\/\/flcube.com\/?p=61812","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-30T07:13:35+00:00","article_modified_time":"2026-03-30T07:13:36+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3004.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=61812#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=61812"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly\u2019s Taltz-Zepbound Combo Shows Superior Efficacy in Obese Psoriatic Arthritis Patients in Phase IIIb TOGETHER-PsA Trial","datePublished":"2026-03-30T07:13:35+00:00","dateModified":"2026-03-30T07:13:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=61812"},"wordCount":398,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=61812#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3004.webp","keywords":["Auto-immune","Clinical trial results","Eli Lilly","NYSE: LLY"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=61812#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=61812","url":"https:\/\/flcube.com\/?p=61812","name":"Eli Lilly\u2019s Taltz-Zepbound Combo Shows Superior Efficacy in Obese Psoriatic Arthritis Patients in Phase IIIb TOGETHER-PsA Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=61812#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=61812#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3004.webp","datePublished":"2026-03-30T07:13:35+00:00","dateModified":"2026-03-30T07:13:36+00:00","description":"Eli Lilly and Company (NYSE: LLY) reported positive top-line results from the TOGETHER-PsA Phase IIIb open-label trial, demonstrating that the combination of Taltz\u00ae (ixekizumab) and Zepbound\u2122 (tirzepatide) achieved statistically superior efficacy versus Taltz monotherapy in adults with active psoriatic arthritis (PsA) who are overweight or obese and have at least one weight-related comorbidity. At the 36-week primary endpoint, the dual-therapy regimen met all primary and key secondary endpoints, reinforcing Lilly\u2019s strategy of integrating its immunology and metabolic franchises.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=61812#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=61812"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=61812#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3004.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3004.webp","width":1080,"height":608,"caption":"Eli Lilly\u2019s Taltz-Zepbound Combo Shows Superior Efficacy in Obese Psoriatic Arthritis Patients in Phase IIIb TOGETHER-PsA Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=61812#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly\u2019s Taltz-Zepbound Combo Shows Superior Efficacy in Obese Psoriatic Arthritis Patients in Phase IIIb TOGETHER-PsA Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3004.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61812","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=61812"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61812\/revisions"}],"predecessor-version":[{"id":61818,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61812\/revisions\/61818"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/61817"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=61812"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=61812"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=61812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}